Edition:
United States

Dynavax Technologies Corp (DVAX.O)

DVAX.O on Consolidated Issue listed on NASDAQ Capital Market

22.30USD
16 Oct 2017
Change (% chg)

$0.40 (+1.83%)
Prev Close
$21.90
Open
$21.20
Day's High
$22.40
Day's Low
$19.65
Volume
3,908,557
Avg. Vol
2,563,000
52-wk High
$24.45
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Dynavax Technologies says ‍on August 21 court entered an order preliminarily approving a proposed settlement​
Friday, 1 Sep 2017 04:33pm EDT 

Sept 1 (Reuters) - Dynavax Technologies Corp :Dynavax Technologies Corp says ‍on August 21 court entered an order preliminarily approving a proposed settlement​.Dynavax Technologies - ‍proposed settlement does not involve stockholder class actions consolidated under caption in re Dynavax securities litigation​.Dynavax Technologies Corp - ‍litigation is currently pending in United States district court, northern district of California​.  Full Article

Vectura says global development agreement with Dynavax
Wednesday, 16 Aug 2017 02:00am EDT 

Aug 16 (Reuters) - VECTURA GROUP PLC ::GLOBAL DEVELOPMENT AGREEMENT WITH DYNAVAX.VECTURA'S AKITA SMART NEBULISER TO BE USED BY DYNAVAX TO DELIVER DV281.VECTURA ELIGIBLE TO RECEIVE MODEST MILESTONES, DEVELOPMENT SERVICES REVENUES.DOES NOT EXPECT MATERIAL IMPACT ON R&D EXPENDITURE WHICH REMAINS WITHIN PREVIOUS ANNUAL GUIDANCE RANGE OF £65-75M FOR 2017 AND 2018.  Full Article

Dynavax prices public offering of common stock
Wednesday, 9 Aug 2017 08:20pm EDT 

Aug 10 (Reuters) - Dynavax Technologies Corp -:Dynavax prices public offering of common stock.Announces public offering of 5 million units at a public offering price of $15 per common unit.  Full Article

Dynavax announces proposed public offering of common stock
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Dynavax Technologies Corp :Dynavax announces proposed public offering of common stock.Dynavax Technologies Corp - ‍intends to offer and sell $125.0 million of shares of its common stock​.Dynavax-Sees using proceeds from proposed offering to fund activities associated with preparing for anticipated U.S. Commercial launch of Heplisav-B​.  Full Article

Dynavax reports Q2 loss per share $0.41
Wednesday, 2 Aug 2017 06:00am EDT 

Aug 2 (Reuters) - Dynavax Technologies Corp :Dynavax reports second quarter 2017 financial results.Q2 loss per share $0.41.Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Dynavax Technologies Corp - Qtrly total revenues $105,000 versus $2,647,000.  Full Article

Point72 Asset Management reports 5.2 pct passive stake in Dynavax Technologies Corp
Tuesday, 6 Jun 2017 04:26pm EDT 

June 6 (Reuters) - Dynavax Technologies Corp : :Point72 Asset Management LP reports 5.2 percent passive stake in Dynavax Technologies Corp as of June 5 .  Full Article

Dynavax reports Q1 loss per share $0.60
Monday, 8 May 2017 06:00am EDT 

May 8 (Reuters) - Dynavax Technologies Corp : :Dynavax reports first quarter 2017 financial results.Q1 loss per share $0.60.Q1 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Dynavax Technologies Corp - qtrly cash, cash equivalents and marketable securities were $85.4 million at march 31, 2017 compared to $81.4 million at December 31, 2016.Dynavax Technologies-during Q1, recorded $2.8 million related to severance, other termination benefits and outplacement services related to Jan restructuring.  Full Article

Dynavax says PDUFA date for HEPLISAV-B remains unchanged
Monday, 3 Apr 2017 06:00am EDT 

Dynavax Technologies Corp : Dynavax announces FDA advisory committee meeting to review HEPLISAV-B . Dynavax Technologies Corp - PDUFA date for HEPLISAV-B remains unchanged .Dynavax -U.S. FDA informed co that VRBPAC will review HEPLISAV-B, hepatitis b vaccine, recombinant (adjuvanted)] at its meeting scheduled for July 28, 2017.  Full Article

Dynavax technologies Q4 loss per share $0.56
Monday, 13 Mar 2017 06:00am EDT 

Dynavax Technologies Corp : Q4 revenue $7.3 million versus $0.7 million . Dynavax technologies says had cut workforce by about 40 percent as part of jan. restructuring . Dynavax reports fourth quarter and year end 2016 financial results and company update . Q4 revenue view $1.5 million -- Thomson Reuters I/B/E/S . Dynavax technologies corp qtrly loss per share $0.56 . Q4 earnings per share view $-0.85, revenue view $1.5 million -- Thomson Reuters I/B/E/S .Dynavax technologies as part of jan. Restructuring, suspended manufacturing activities, commercial preparations,other longer term investment related to Heplisav-B.  Full Article

Dynavax announces FDA acceptance
Tuesday, 28 Feb 2017 04:01pm EST 

Dynavax Technologies Corp : Dynavax announces FDA acceptance for review of its complete response to November 2016 CRL and PDUFA action date for heplisav-b(tm) .Dynavax Technologies Corp- FDA has established August 10, 2017 as prescription drug user fee act (PDUFA) action date for heplisav-b(tm).  Full Article

Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.